208 related articles for article (PubMed ID: 18582548)
1. Polymorphic control of inhalation microparticles prepared by crystallization.
Murnane D; Marriott C; Martin GP
Int J Pharm; 2008 Sep; 361(1-2):141-9. PubMed ID: 18582548
[TBL] [Abstract][Full Text] [Related]
2. Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization.
Murnane D; Marriott C; Martin GP
Eur J Pharm Biopharm; 2008 May; 69(1):94-105. PubMed ID: 17981448
[TBL] [Abstract][Full Text] [Related]
3. Developing an environmentally benign process for the production of microparticles: amphiphilic crystallization.
Murnane D; Marriott C; Martin GP
Eur J Pharm Biopharm; 2008 May; 69(1):72-82. PubMed ID: 18082385
[TBL] [Abstract][Full Text] [Related]
4. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
Murnane D; Martin GP; Marriott C
J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
[TBL] [Abstract][Full Text] [Related]
5. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids.
Tong HH; Shekunov BY; York P; Chow AH
Pharm Res; 2001 Jun; 18(6):852-8. PubMed ID: 11474791
[TBL] [Abstract][Full Text] [Related]
6. Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals.
Murnane D; Martin GP; Marriott C
Pharm Res; 2008 Oct; 25(10):2283-91. PubMed ID: 18509598
[TBL] [Abstract][Full Text] [Related]
7. Thermal analysis of trace levels of polymorphic impurity in salmeterol xinafoate samples.
Tong HH; Shekunov BY; York P; Chow AH
Pharm Res; 2003 Sep; 20(9):1423-9. PubMed ID: 14567637
[TBL] [Abstract][Full Text] [Related]
8. Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.
Das S; Larson I; Young P; Stewart P
Eur J Pharm Sci; 2009 Jun; 37(3-4):442-50. PubMed ID: 19491036
[TBL] [Abstract][Full Text] [Related]
9. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation.
Adi H; Larson I; Stewart PJ
Int J Pharm; 2007 Jun; 337(1-2):229-38. PubMed ID: 17303354
[TBL] [Abstract][Full Text] [Related]
10. Predicting the aerosol performance of dry powder inhalation formulations by interparticulate interaction analysis using inverse gas chromatography.
Tong HH; Shekunov BY; York P; Chow AH
J Pharm Sci; 2006 Jan; 95(1):228-33. PubMed ID: 16315225
[TBL] [Abstract][Full Text] [Related]
11. Solid-state characterization of two polymorphic forms of R-albuterol sulfate.
Palacio MA; Cuffini S; Badini R; Karlsson A; Palacios SM
J Pharm Biomed Anal; 2007 Mar; 43(4):1531-4. PubMed ID: 17141446
[TBL] [Abstract][Full Text] [Related]
12. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
Gaisford S; Dennison M; Tawfik M; Jones MD
Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
[TBL] [Abstract][Full Text] [Related]
13. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
Handoko A; Ian L; Peter SJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):265-74. PubMed ID: 18996188
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution enhancement of micronized l-nimodipine by antisolvent re-crystallization from its crystal form H.
Zu Y; Li N; Zhao X; Li Y; Ge Y; Wang W; Wang K; Liu Y
Int J Pharm; 2014 Apr; 464(1-2):1-9. PubMed ID: 24456674
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.
Jaffari S; Forbes B; Collins E; Khoo J; Martin GP; Murnane D
Pharm Res; 2014 Dec; 31(12):3251-64. PubMed ID: 25015552
[TBL] [Abstract][Full Text] [Related]
16. Solid-state chemistry and particle engineering with supercritical fluids in pharmaceutics.
Pasquali I; Bettini R; Giordano F
Eur J Pharm Sci; 2006 Mar; 27(4):299-310. PubMed ID: 16388936
[TBL] [Abstract][Full Text] [Related]
17. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
Chiou H; Li L; Hu T; Chan HK; Chen JF; Yun J
Int J Pharm; 2007 Feb; 331(1):93-8. PubMed ID: 17052870
[TBL] [Abstract][Full Text] [Related]
18. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids.
Tong HH; Shekunov BY; York P; Chow AH
Pharm Res; 2002 May; 19(5):640-8. PubMed ID: 12069167
[TBL] [Abstract][Full Text] [Related]
19. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate.
Shariare MH; de Matas M; York P
Int J Pharm; 2011 Aug; 415(1-2):62-72. PubMed ID: 21683128
[TBL] [Abstract][Full Text] [Related]
20. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios.
Adi H; Larson I; Chiou H; Young P; Traini D; Stewart P
J Pharm Sci; 2008 Aug; 97(8):3140-52. PubMed ID: 18023007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
